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Summary
Objective: We have sought to determine if markers of proteoglycans and collagen type II (CII) degradation can be detected at an early stage
following acute knee injury in the synovial fluid (SF) from a group of patients diagnosed with non-infectious knee joint synovitis (KJS). CII,
proteoglycans and elastase activity in the SF from patients with KJS were compared to SF from patients with two chronic arthritis conditions:
osteoarthritis (OA) and rheumatoid arthritis (RA) as well as normal SF controls.
Methods: CII peptides were measured by sandwich ELISA using two monoclonal antibodies: 8:6:D8, a CII-specific antibody, and 14:7:D8
which binds to an amino acid sequence on CII as well as collagens type I, III and V. Epitope 9A4, a neo-epitope resulting from collagenase
digestion of CI, CII, and CIII was measured by inhibition ELISA. Proteoglycans measurement included total sulfated glycosaminoglycans
(sGAG) by dye-binding assay and 5-D-4 epitope, a keratan sulfate epitope, by inhibition ELISA. Elastase activity was measured
colorimetircally using N-succinyl trialanine p-nitroanilide (SANA) substrate.
Results: The quantified CII peptide concentrations by sandwich and inhibition ELISA were significantly higher in SF from patients with
KJS (P<0.05) compared to SF from patients with OA, RA and normal aspirates. 5-D-4 and sGAG concentrations were significantly lower
(P<0.05) in SF from patients with KJS compared to SF from patients with OA and RA. Elastase activity in SF from patients with KJS and RA
were significantly higher (P<0.05) than SF from patients with OA. A significant correlation exists between elastase activity and 9A4 epitope
concentration in SF from patients with KJS.
Conclusion: The elevated CII peptides concentrations in KJS SF compared to normal and OA aspirates indicate early signs of cartilage
network damage. The low proteoglycans concentrations in SF from patients with KJS may indicate that injury is limited to the superficial zone
of cartilage in the patient population studied. The high elastase activity in SF from patients with KJS and RA are linked to the high CII peptides
concentration. The elastase activity in the SF from patients with KJS is due to the action of neutrophil elastase (NE) and collagenases, where
both contribute to the destruction of the articular cartilage.
© 2003 Published by Elsevier Ltd on behalf of OsteoArthritis Research Society International.
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Introduction
Chronic arthritis conditions, osteoarthritis (OA) and rheu-
matoid arthritis (RA), are characterized by irreversible
damage to the cartilage matrix caused by enzymatic deg-
radation of the two major components of cartilage: collagen
type II (CII) and aggrecan1–4. As a result of this breakdown,
molecular markers of aggrecan and CII degradation appear
in the synovial fluids (SF) of the affected joints. Sulfated
glycosaminoglycans (sGAG) in SF indicate the extent of
aggrecan degradation4. Monoclonal antibodies against CII
molecule have been developed and utilized in ELISA
immunoassays to measure CII fragments in the SF5–7.
Acute knee injury either due to injury or repetitive impact
loading is recognized as an apparent and distinct prevent-
able cause of secondary OA8. The mechanism by which
secondary OA develops after acute knee injury is still
unclear. Evidence of cartilage damage, if present, at an
early stage following knee injury can help explain the
biochemical processes that can lead to the late develop-
ment of secondary OA. This study sought to examine the
presence of molecular markers of CII and proteoglycans
degradation in the SF from a patient population diagnosed
with non-infectious knee joint synovitis (KJS) at an early
stage following a knee injury.
CII and proteoglycans SF concentrations of patients with
KJS were compared to those of two patient groups with
chronic arthritis conditions: OA and RA. The elastase
activity among the three patient groups was compared and
potential correlations between elastase activity in SF from
patients with KJS and cartilage matrix degradation were
investigated. A novel sandwich ELISA was developed for
this investigation using 18:6:D6, a CII-specific antibody that
reacts with epitopes on cyanogen bromide (CNBr) cleaved
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peptides CB 9.7 and CB 119, and 14:7:D8 which reacts with
an identical amino acid sequence in CII as well as col-
lagens type I, III and V9. The C-terminal neo-epitope
derived from collagenase degradation of fibrillar collagen
was quantified using monoclonal antibody 9A46. Measure-
ment of proteoglycan degradation included sGAG and
5-D-4 SF concentrations.
Patients and methods
STUDY DESIGN
This was an observational study of CII and proteoglycans
degradation markers in aspirated SF from an emergency
department patient population presenting with an acute
knee injury as compared to SF from patients with advanced
arthritis conditions and normal SF aspirates.
STUDY SETTING AND PATIENT SELECTION
Patients diagnosed with KJS (48 patients) were enrolled
in the study. Institutional review board (IRB) approvals were
obtained prior to the initiation of the study. Aliquots of SF
were taken from both pediatric and adult emergency
department patients undergoing diagnostic knee joint
arthrocentesis. Inclusion criteria for patients with KJS
included monoarticular knee joint effusions judged to be
clinically significant, requiring arthrocentesis in the absence
of radiographic evidence of fracture. Exclusion criteria
included a diagnosis of occult fracture, history of sickle cell
anemia or hemophilia, patellar bursitis, gout, pseudogout,
and samples contaminated with blood.
An 18-gauge needle was used, under aseptic tech-
niques, to aspirate SF from the lateral aspect of the
affected knee joint following anesthesia of the site with 2%
lidocaine. Aspirations were performed by both emergency
medicine attendings and resident physicians. Informed
consent was not obtained, as these were samples, which
would otherwise be discarded.
Aspirates were also obtained from patients diagnosed
with a Noyes criteria grade III or IV OA, 72 patients, and
patients diagnosed with RA, 20 patients. These were
obtained during arthroscopy and rheumatologic evaluation,
respectively. Normal human SF was obtained from human
subjects postmortem who showed no signs of gross degen-
erative joint disease following fatal accidents. These
samples were obtained in gratis from Dr Martin Lotz at
Scripps Research Institute.
HYALURONIDASE SF TREATMENT
SF samples were collected, aliquoted and stored at
−70°C. Sample aliquots used in the elastase activity
assays were not treated with EDTA. Other aliquots were
treated with 5 mM EDTA and centrifuged at 10 000 rpm for
15 min to remove debris. SF samples were treated with
streptomyces hyaluronidase (Sigma–Aldrich, Saint Louis,
MO, USA) to a final concentration of 200 U/ml for 40 min at
56°C and subsequently for 20 min at 80°C.
SANDWICH ELISA FOR CII PEPTIDES
Two CII monoclonal antibodies, 18:6:D6 and 14:7:D8,
were used in this assay9. Antibody 18:6:D6 was made
against CII CNBr cleavage peptide 9.7 coupled to ovalbu-
min. Antibody 14:7:D8 was made using a 15 amino acid
synthetic peptide GPQGPRGDKGEAGEP coupled to KLH
and was conjugated to horseradish peroxidase by using
EZ-Link maleimide activated horseradish peroxidase kit
(Pierce Chemicals, Rockford, IL, USA). Microtiter plates
(High binding Costar, Corning Inc., Corning, NY, USA) were
coated with a 1:500 dilution of 18:6:D6 antibody in phos-
phate buffer saline (PBS) overnight. Each well received
100 µl of the antibody solution. Hyaluronidase-pre-treated
SF samples (serial dilutions in PBS–Tween 20), CNBr
cleaved CII peptides spiked SF samples and standards
(different dilutions of CNBr cleaved CII peptides) were
incubated on the pre-coated plates for 60 min at room
temperature. Antibody 14:7:D8 conjugated with peroxidase
in PBS–Tween, a 1:1000 dilution, was subsequently added
for 60 min at room temperature. Fluorescence substrate
developing solution (100 µl) (QuantaBlu™, Pierce) was
added for 60 min and the fluorescence was measured at
an excitation wavelength 330 nm and an emission wave-
length 460 nm using a Packard Fluorocounter (Packard
Instruments, Meriden, CT, USA).
TOTAL PROTEIN LEVELS
Total protein concentrations of SF samples were deter-
mined colorimetrically using Micro BCA™ Protein Assay
Reagent Kit (Pierce). A series of bovine serum albumin
standards, 100 µl, (100–2 µg/ml) as well as SF samples
diluted in distilled water, 100 µl, were incubated with Micro
BCA reagent, 100 µl in the wells of a 96-well plate for
60 min at 37°C. The absorbance was subsequently
measured at 570 nm using a Dynex MRX microtiter plate
reader (Dynex Technologies, Chantilly, VA, USA).
DETERMINATION OF HYALURONATE CONCENTRATION
SF samples were assayed by the manual carbazole
reaction for uronic acid10. SF samples, diluted in PBS
(125 µl) were mixed with concentrated H2SO4 containing
25 mM sodium borate previously cooled to −70°C (750 µl).
The mixture was heated at 100°C for 10 min and subse-
quently cooled to room temperature. Carbazole solution in
absolute ethanol, 0.125% (w/v) was subsequently added to
the reaction mixture (25 µl). After heating at 100°C for
15 min, the presence of hyaluronate was indicated by a
pink color that was measured spectrophotometrically at
530 nm.
INHIBITION ELISA FOR 9A4 EPITOPE
Antibody 9A4 was kindly provided by Dr Ivan Otterness,
Pfizer Central Research, Groton, CT. A proline rich, nine
amino acid peptide AEGPPGPQG to which 9A4 has shown
a high binding affinity11, was synthesized using fmoc
chemistry and used to coat microtiter plates at a final
concentration of 500 ng/ml in 50 mM sodium carbonate
buffer, pH 9.5 overnight at 4°C. The nine amino acid peptide
in serial dilutions (2–0.001 µg/ml) and hyaluronidase-pre-
treated SF samples were incubated with equal volumes of
9A4 antibody (1:1000) dilution in PBS–Tween overnight at
room temperature. Samples of the standards or the SF
treated with 9A4 antibody (100 µl) were incubated on the
pre-coated microtiter plates for 60 min at room temperature.
Goat anti-mouse IgG (H+L)-HRP conjugate (Bio Rad,
Hercules, CA, USA), 1:1000 dilution in PBS–Tween was
subsequently added for 60 min at room temperature. The
assay was developed using a fluorescence substrate in a
manner identical to the CII sandwich ELISA.
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INHIBITION ELISA FOR 5-D-4 EPITOPE
Microtiter plates were coated with chondroitinase-ABC
treated12 bovine aggrecan monomer A1D1 to a final con-
centration of 1 µg/ml in 50 mM sodium carbonate buffer, pH
9.5 overnight at 4°C. Standard bovine aggrecan A1D1
monomer in serial concentrations (4–0.03 µg/ml) and
hyaluronidase-treated SF samples were incubated with
equal volumes of 5-D-4 antibody (ICN Biomedicals Inc.,
Irvine, CA, USA), 1:10 000 dilution in PBS–Tween, over-
night at room temperature. Samples of the standards or the
SF treated with 5-D-4 antibody (100 µl) were incubated on
the pre-coated microtiter plates for 60 min at room tem-
perature. The assay was further developed in a method
similar to the ELISA for 9A4 epitope.
DETERMINATION OF TOTAL SGAG
Total sGAG levels were determined by the 1,9-dimethyl-
methylene blue (DMB; Sigma–Aldrich) dye-binding
assay13. Bovine tracheal chondroitin sulfate (Sigma–
Aldrich) was serially diluted in distilled deionized water as
a standard and the shift in absorbance was measured
immediately after adding the dye solution at 570 nm.
ELASTASE ACTIVITY IN SF
Hydrolysis of a low molecular weight synthetic substrate
N-succinyl trialanine p-nitroanilide (SANA, Sigma–Aldrich),
which releases p-nitroaniline, was measured spectrophoto-
metrically at 410 nm14 and used as a measure of SF
elastase activity. Pancreatic porcine elastase type I (6.8 U/
mg, Sigma–Aldrich) was used to construct a standard
curve. One unit of the enzyme was defined as 1.0 µmol of
SANA hydrolyzed per minute at 25°C. In another set of
experiments, SF samples were pre-incubated with 1 mM
p-aminophenylmercuric acetate (p-APMA, Sigma–Aldrich)
for 4 h at 37°C to activate proMMPs, and the elastase
activity was subsequently measured. Elastase activity of
SF samples was expressed as µU/ml. To inhibit metal
dependent elastase activity in the SF, SF samples were
pre-incubated with 10 mM EDTA solution for 3 h at
37°C, and elastase activity was measured as described
previously.
STATISTICAL TESTS
Epitope concentrations and elastase enzyme activity of
KJS, OA and RA SF samples were represented by box plot
graphs. The solid line represents the median, the box
represents the middle 50% of values, the error bars repre-
sent the 10th and 90th percentile and individual points
represent outlying values. Mean levels were reported for
CII peptides, 9A4 epitope, and 5-D-4 concentrations, and
elastase activity. Student’s unpaired two-sample t test was
used to test for differences in the markers measured among
the patient groups. The significance level was determined
a priori to be α0.05. Correlations between elastase
activity and both CII peptides and 9A4 epitope concen-
trations of SF from patients with KJS were performed by
Spearman’s correlation, and the coefficient of correlation
was also reported.
Results
CII PEPTIDES
A total of 74% of KJS SF samples had detectable
quantities of CII peptides compared to 89% in OA SF
samples, and 90% in RA SF samples (Fig. 1). Postmortem
normal SF samples had undetectably low CII peptide
concentrations (<50 ng/ml). The CII peptides in SF from
patients with KJS showed a wide range of concentrations
between 0.07 and 3.37 µg/ml, a mean of 0.94 µg/ml, 95%
CI (0.86–1.20 µg/ml). The OA and RA SF aspirates had
means of 0.13 µg/ml, 95% CI (0.12–0.15 µg/ml) and
0.17 µg/ml, 95% CI (0.14–0.19 µg/ml), respectively. CII
peptide concentrations were significantly higher in SF
samples from patients with KJS compared to SF samples
from either patients with OA, (P<0.001), or RA (P<0.001).
In addition, CII peptide concentrations in SF from patients
with RA were significantly higher than patients with OA
Fig. 1. Collagen type II (CII) peptides concentrations in SF from patients with KJS, OA and RA using a sandwich ELISA. * CII peptides
concentrations in KJS were significantly higher (P<0.001) than both OA and RA aspirates. ** CII peptides concentrations in RA were
significantly higher (P<0.001) than OA aspirates.
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(P<0.001). To control for variations in CII peptide concen-
trations resulting from differences in volume of aspirated SF
samples among patient groups, hyaluronic acid and total
protein were quantified (data not shown), and CII peptide
concentrations were normalized to hyaluronic acid and total
protein concentrations. Hyaluronic acid concentration
showed no significant difference between the three patient
groups. Total protein concentrations were significantly
higher in patients with KJS (P<0.005) compared to OA and
RA SF samples, with no significant differences between OA
and RA SF concentrations. When CII peptide concen-
trations were normalized to hyaluronate and total protein
concentrations, the significant elevation of CII peptides
concentrations in patients with KJS compared to patients
with OA and RA (P<0.005) was still apparent.
9A4 EPITOPE
A total of 65% of KJS SF samples had detectable
quantities of 9A4 epitope compared to 78 and 85% in OA
and RA SF, respectively (Fig. 2). The mean concentrations
of 9A4 epitope were 4.52, 2.36, and 3.71 µg/ml for patients
with KJS, OA and RA, respectively. Concentrations of 9A4
epitope in KJS SF were significantly higher than OA SF
(P0.012) but not different from RA SF concentrations
(P0.448). There were no significant differences in 9A4
epitope concentrations between SF from patients with RA
and OA (P0.119). The 9A4 inhibition ELISA is indicative
of early signs of articular cartilage damage leading to the
production of active collgenolytic activity, which can release
collagen peptides.
5-D-4 EPITOPE
Total sGAG was measured by DMB dye-binding assay,
and 5-D-4 epitope was quantified using inhibition ELISA.
Mean sGAG concentrations in SF from patients with KJS
were significantly lower (P<0.005) than either OA or RA
samples, while there was no significant differences in
sGAG SF levels between OA and RA (data not shown).
A total of 60% of KJS, 82% of OA and 75% of RA SF
samples contained detectable quantities of 5-D-4 epitope
Fig. 2. Epitope 9A4 concentration by inhibition ELISA in SF from patients with KJS, OA and RA. * Epitope 9A4 concentration in KJS was
significantly higher (P0.012) than OA aspirates.
Fig. 3. Epitope 5-D-4 keratan sulfate concentration by inhibition ELISA in SF from patients with KJS, OA and RA. * 5-D-4 epitope
concentration in OA was significantly higher (P<0.05) than KJS aspirates. ** 5-D-4 epitope concentration in RA was significantly higher
(P<0.05) than OA aspirates.
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(Fig. 3). SF from patients with KJS showed significantly
lower concentrations of sGAG and 5-D-4 keratan sulfate
epitope compared to SF from patients with either OA or RA.
ELASTASE ACTIVITY
A total of 44% of patients with KJS had detectable
elastase activity compared with 72% in patients with OA
and 75% in patients with RA [Fig. 4(a)]. The mean value for
elastase activity in KJS aspirates was 5.12 µU/ml, com-
pared to 0.40 µU/ml in OA aspirates and 4.99 µU/ml in RA
aspirates. Elastase activity in SF from patients with KJS
and RA were both significantly higher than SF from patients
with OA (P<0.001) and (P<0.001), respectively. Activation
of prometalloproteinases by p-APMA caused a significant
elevation in elastase activity in SF from patients with OA
(P<0.001). Although the mean values for elastase activity in
KJS aspirates slightly increased, there was no significant
elevation in either KJS or RA SF samples.
To further investigate the source of elastase activity in the
SF samples, EDTA was added to abolish metal dependent
elastase activity [Fig. 4(b)]. The mean inhibition of elastase
activity by EDTA in KJS aspirates was calculated to be
approximately 43% compared to 65% in OA aspirates and
80% in RA aspirates.
Correlations of elastase activity to CII peptide concen-
tration [Fig. 5(a)] and 9A4 epitope concentration [Fig. 5(b)]
were calculated to establish a relationship between
elastase activity and CII degradation in SF from patients
with KJS. The correlation between elastase activity and
CII peptide concentration was not significant (r0.397;
P0.128). On the other hand, there was a significant
correlation between elastase activity and 9A4 epitope
concentrations (r0.583; P0.009).
Discussion
In this study, CII peptide concentrations in the SF from
patients diagnosed with KJS, OA and RA were reported
using a novel sandwich, CII-specific, ELISA. The elevated
CII peptide concentrations in SF from patients with KJS
compared to normal controls and OA aspirates indicate
early signs of cartilage network damage. Elevated 9A4
Fig. 4. Elastase activity in SF from patients with KJS, OA and RA using SANA substrate. (a) Elastase activity in SF from patients with KJS,
OA and RA. * Elastase activity in KJS was significantly higher (P<0.05) than OA aspirates. ** Elastase activity in RA was significantly higher
(P<0.05) than OA aspirates. (b) Inhibition of elastase activity in KJS, OA and RA SF by EDTA treatment.
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epitope concentration in SF from patients with KJS indi-
cates active metalloproteinase activity in these patients.
Epitope 9A4 is produced when CI, CII, and CIII are
degraded by the collagenase subfamily of MMPs6. The
presence of elevated 9A4 epitope concentrations in SF
from KJS patients suggests that MMP-1, MMP-8 or
MMP-13 contribute to the degradation of cartilage matrix
following injury. Elevated expression of chondrocyte
MMP-13 was reported following acute injury11, and expres-
sion of MMP-1 in traumatic synovial membrane has also
been identified15. All these findings point to an important
role of MMPs in the degradation of cartilage matrix in
traumatic conditions.
The higher elastase-like activity in SF from RA and KJS
compared to OA results from increased concentrations of
either neutrophil elastase (NE) or MMPs in SF. NE is a
serine protease that degrades connective tissue com-
ponents such as elastin, and proteoglycans16. NE cleaves
native helical CI, CIII, and CX17. Helical CII is resistant to
cleavage by NE17. In addition to its direct collagenolytic
activity, NE was shown to activate MMPs18 and inactivate
their tissue inhibitors19, thus causing an imbalance that
favors increased collagenolytic activity. NE also plays a
significant role in the pathology and progression of RA20.
In KJS aspirates, early elevation of metal dependent
elastase activity may contribute to the CII degradation and
release into the SF. The different types of collagens are
arranged in a unique spatial arrangement that excludes CII
from the outer layer of articular cartilage. NE, and not
collagenases, was shown to be implicated in the destruc-
tion of the outer cartilage layer, exposing the underlying
collagen matrix21. It is possibly the concerted action of NE,
through destruction of the superficial layer of cartilage and
degradation of proteoglycans leading to better accessibility
of CII molecules, and collagenases, through specific cleav-
age of CI, and CII, that combined lead to damage to the
superficial layer of cartilage and release of CII fragments in
the SF.
The sGAG and 5-D-4 are markers of matrix turnover and
degradation. The lower concentrations reported for sGAG
and 5-D-4 in SF from patients with KJS suggest that injury
is confined to the superficial zone of cartilage among this
Fig. 5. Correlations between elastase activity and collagen type II epitopes concentrations in SF from patients with KJS. (a) Correlation
between elastase activity and CII peptides concentrations. r0.397, P0.128. (b) Correlation between elastase activity and 9A4 epitope
concentration. r0.583, P0.008.
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population. Our sGAG measurements are in agreement
with other reports that found no significant differences
between sGAG concentrations in SF from patients with OA
and RA22. Analysis of full-depth articular cartilage for its
sGAG content revealed that CS content is highest in the
mid-zone while KS content progressively increases through
the depth of the cartilage23. This may explain that the low
levels of release of sGAG in KJS aspirates are due to a
superficial injury to the articular cartilage.
Collection of SF samples in our study was performed
with extreme care. The samples were processed quickly
after aspiration and stored frozen to minimize any proteo-
lytic degradation after aspiration. Synovial effusion can lead
to dilution of the cartilage degradation markers measured in
this study. Therefore, hyaluronate concentration was deter-
mined, and CII peptides concentrations were normalized to
hyaluronate concentration. Hyaluronate is locally produced
by the synovium. Total protein concentrations were also
used to identify any variations resulting from synovial
effusion. The higher protein concentrations in SF from
patients with KJS can be a result of infiltration of low
molecular weight proteins through the synovial membrane
under inflammatory conditions.
The results of this study delineate early signs of cartilage
degradation in a patient group with KJS. Patients diag-
nosed with KJS represent a new population of study
subjects to the rheumatologic and orthopedic research
communities. These patients are primarily cared for by
emergency physicians and do not receive routine ortho-
pedic follow-up. These patients have not been subjected
to previous cartilage degradation marker studies. They
appear to have an injury that is confined to the superficial
zone of articular cartilage. The cascade of events leading to
the release of collagen type II peptides and aggrecan in the
SF of patients with KJS is not fully understood, however,
collagenases and NE play a role in the degradation
process.
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